PriceTargets.com logo

Achieve Life Sciences - ACHV Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.25
  • Forecasted Upside: 277.46%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$4.57 As of 04/17/2024 01:00 AM ET
▲ +0.19 (4.34%)

This chart shows the closing price for ACHV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Achieve Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACHV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACHV

Analyst Price Target is $17.25
▲ +277.46% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Achieve Life Sciences in the last 3 months. The average price target is $17.25, with a high forecast of $20.00 and a low forecast of $11.00. The average price target represents a 277.46% upside from the last price of $4.57.

This chart shows the closing price for ACHV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Achieve Life Sciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/18/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2024JonestradingInitiated CoverageBuy$20.00Low
4/1/2024OppenheimerReiterated RatingOutperform ➝ Outperform$18.00Low
3/5/2024Lake Street CapitalLower TargetBuy ➝ Buy$19.00 ➝ $11.00Low
12/12/2023OppenheimerLower TargetOutperform ➝ Outperform$21.00 ➝ $18.00Low
5/31/2023Lake Street CapitalLower Target$22.00 ➝ $19.00Low
5/10/2023Maxim GroupBoost TargetBuy$8.00 ➝ $20.00Low
3/17/2023Maxim GroupReiterated RatingBuy$8.00Low
3/17/2023OppenheimerReiterated RatingOutperform$17.00Low
11/16/2022Maxim GroupLower TargetBuy$21.00 ➝ $8.00Low
11/15/2022OppenheimerLower Target$27.00 ➝ $20.00Low
4/27/2022OppenheimerBoost Target$23.00 ➝ $27.00High
3/11/2022HC WainwrightReiterated RatingBuy$24.00Medium
10/4/2021Alliance Global PartnersInitiated CoverageBuy$25.00High
8/26/2021HC WainwrightReiterated RatingBuy$24.00High
6/25/2021Maxim GroupReiterated RatingBuy$21.00High
6/23/2021OppenheimerInitiated CoverageOutperform$23.00High
5/14/2021Maxim GroupInitiated CoverageBuy$21.00Low
4/6/2021HC WainwrightReiterated RatingBuyLow
3/12/2021Maxim GroupReiterated RatingBuy$21.00High
9/18/2020Maxim GroupInitiated CoverageBuy$21.00High
9/17/2020Lake Street CapitalInitiated CoverageBuy$30.00High
8/21/2020Maxim GroupReiterated RatingBuyHigh
8/7/2020LADENBURG THALM/SH SHReiterated RatingBuy$100.00Low
6/30/2020Maxim GroupReiterated RatingBuy$40.00High
5/19/2020Maxim GroupInitiated CoverageBuy$40.00Low
2/25/2020HC WainwrightInitiated CoverageBuy$40.00High
10/1/2019Maxim GroupReiterated RatingBuy$120.00Low
9/24/2019Maxim GroupReiterated RatingBuy$120.00High
8/9/2019Maxim GroupSet TargetBuy$120.00High
8/9/2019LADENBURG THALM/SH SHReiterated RatingBuy$400.00High
7/24/2019Maxim GroupReiterated RatingBuy$120.00Low
6/21/2019Maxim GroupSet TargetBuy$120.00Low
6/14/2019Maxim GroupInitiated CoverageBuy$120.00High
6/11/2019LADENBURG THALM/SH SHSet TargetPositive ➝ Buy$240.00 ➝ $400.00High
(Data available from 4/17/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2023
  • 6 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
2/17/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2024
  • 2 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/17/2024

Current Sentiment

  • 2 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Achieve Life Sciences logo
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Read More

Today's Range

Now: $4.57
Low: $4.47
High: $4.59

50 Day Range

MA: $4.42
Low: $3.82
High: $4.67

52 Week Range

Now: $4.57
Low: $3.03
High: $10.30

Volume

53,105 shs

Average Volume

89,054 shs

Market Capitalization

$156.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Achieve Life Sciences?

The following Wall Street sell-side analysts have issued reports on Achieve Life Sciences in the last year: Jonestrading, Lake Street Capital, Maxim Group, and Oppenheimer Holdings Inc..
View the latest analyst ratings for ACHV.

What is the current price target for Achieve Life Sciences?

4 Wall Street analysts have set twelve-month price targets for Achieve Life Sciences in the last year. Their average twelve-month price target is $17.25, suggesting a possible upside of 277.5%. Maxim Group has the highest price target set, predicting ACHV will reach $20.00 in the next twelve months. Lake Street Capital has the lowest price target set, forecasting a price of $11.00 for Achieve Life Sciences in the next year.
View the latest price targets for ACHV.

What is the current consensus analyst rating for Achieve Life Sciences?

Achieve Life Sciences currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACHV will outperform the market and that investors should add to their positions of Achieve Life Sciences.
View the latest ratings for ACHV.

What other companies compete with Achieve Life Sciences?

Other companies that are similar to Achieve Life Sciences include Alpha Teknova, VolitionRx, ARCA biopharma, Aspira Women's Health and ImmuCell. Learn More about companies similar to Achieve Life Sciences.

How do I contact Achieve Life Sciences' investor relations team?

Achieve Life Sciences' physical mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company's listed phone number is (604) 210-2217 and its investor relations email address is [email protected]. The official website for Achieve Life Sciences is achievelifesciences.com. Learn More about contacing Achieve Life Sciences investor relations.